A new artificial intelligence tool developed at Cedars-Sinai could transform how physicians select presurgical therapies for breast cancer patients. The tool, named BRIDGE, was detailed in the journal Annals of Oncology alongside early validation data, according to a press release. BRIDGE reads genetic signals inside a tumor to identify which subtypes are present, rather than categorizing the entire mass into a single subtype. This approach may enable more personalized and effective treatment plans.
Breast cancer is a heterogeneous disease, meaning that a single tumor can contain multiple subtypes with different genetic profiles. Traditional methods often classify tumors based on the dominant subtype, potentially overlooking less prevalent but aggressive components. BRIDGE addresses this limitation by analyzing the intricate genetic signals within the tumor, providing a comprehensive view of its composition. This granularity could help oncologists choose the most suitable presurgical therapy, such as chemotherapy or targeted agents, to improve outcomes.
The implications of this development are significant for both patients and the broader field of oncology. For patients, more accurate subtype identification could lead to treatments that are better tailored to their specific cancer, potentially reducing side effects and improving survival rates. For the medical community, BRIDGE represents a step toward precision medicine, where treatment decisions are guided by the unique molecular characteristics of each patient's disease. The tool also builds on other advances in cancer research, including work by companies like Calidi Biotherapeutics Inc. (NASDAQ: CLDI), which focuses on developing innovative therapies.
While the validation data is still early, the research suggests that BRIDGE could be a valuable addition to the oncologist's toolkit. By moving beyond one-size-fits-all categorization, the AI tool may help identify patients who would benefit from more aggressive therapy versus those who could be spared unnecessary treatments. As the technology is further tested and refined, it has the potential to become a standard part of breast cancer management.
The development of BRIDGE underscores the growing role of artificial intelligence in healthcare, particularly in oncology. AI systems can process vast amounts of genomic data quickly and accurately, uncovering patterns that might be missed by human analysis. This capability is crucial for diseases like breast cancer, where genetic complexity can influence treatment response. The tool's ability to read genetic signals from within a tumor could also have applications beyond breast cancer, potentially aiding in the management of other cancers with similar heterogeneity.
For now, the focus remains on validating BRIDGE in larger clinical studies. If successful, it could become a key resource for clinicians seeking to optimize presurgical treatment plans, ultimately improving patient outcomes. The research was conducted at Cedars-Sinai, a leading medical center known for its work in precision health and AI-driven diagnostics.
